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The Enhancement or Prevention of Airway
Hyperresponsiveness during Reinfection with Respiratory
Syncytial Virus Is Critically Dependent on the Age at First
Infection and IL-13 Production1
Azzeddine Dakhama,2,3 Jung-Won Park,3 Christian Taube, Anthony Joetham, Annette Balhorn,
Nobuaki Miyahara, Katsuyuki Takeda, and Erwin W. Gelfand
Respiratory syncytial virus (RSV) infection in early life is suspected to play a role in the development of postbronchiolitis wheezing
and asthma. Reinfection is common at all ages, but factors that determine the development of altered airway function after
reinfection are not well understood. This study was conducted in a mouse model to define the role of age in determining the
consequences on airway function after reinfection. Mice were infected shortly after birth or at weaning and were reinfected 5 wk
later, followed by assessment of airway function, airway inflammation, and lung histopathology. Infection of mice at weaning
elicited a protective airway response upon reinfection. In this age group, reinfection resulted in increased airway inflammation,
but without development of airway hyperresponsiveness (AHR) or eosinophilia and decreased IL-13 levels. By contrast, neonatal
infection failed to protect the airways and resulted in enhanced AHR after reinfection. This secondary response was associated
with the development of airway eosinophilia, increased IL-13 levels, and mucus hyperproduction. Both CD4- and CD8-positive T
cells were a source of IL-13 in the lung, and inhibition of IL-13 abolished AHR and mucus production in these mice. Inoculation
of UV-inactivated virus failed to elicit these divergent responses to reinfection, emphasizing the requirement for active lung
infection during initial exposure. Thus, neonatal RSV infection predisposes to the development of airway eosinophilia and en-
hanced AHR via an IL-13-dependent mechanism during reinfection, whereas infection at a later age protects against the devel-
opment of these altered airway responses after reinfection. The Journal of Immunology, 2005, 175: 1876–1883.
R espiratory syncytial virus (RSV)4 is the most commoncause of acute bronchiolitis that primarily affects infantsand young children worldwide (1). In the United States,
RSV bronchiolitis was identified as the leading cause of infant
hospitalization annually between 1997 and 2000, at estimated total
costs of more than $2.6 billion (2). It has also been estimated that
200 deaths occur annually; 80% of these deaths occur among
infants (1 year old) as a result of severe lower respiratory tract
illness caused by RSV (3). Factors that predispose to severe RSV-
related illness include premature birth and pre-existing conditions,
such as bronchopulmonary dysplasia, congenital heart disease, and
immune deficiency (4).
RSV infection can occur throughout life. However, unless im-
munocompromised either naturally or medically (5), adults de-
velop mild symptoms, which are usually restricted to the upper
airways (6). By contrast, individuals of the youngest ages are the
most susceptible to develop severe symptoms, particularly involv-
ing the lower airways (7). Conceivably, because the size of the
airways is smaller in young babies than in older children, they
might be easily obstructed by inflammation, edema, and mucus,
important physical factors that may contribute to the development
of more severe lower respiratory tract illness. However, not all
infants develop severe lower respiratory tract illness after RSV
infection, suggesting that other factors, most likely host immune
responses, are involved in determining and limiting the severity of
the disease (8).
Almost all young children experience RSV infection at least
once in the first few years of life, and 65% become infected
during their first year, with the peak incidence for lower respiratory
disease occurring between 2 and 7 mo of age (7, 9). Most intrigu-
ing, however, is the clinical and epidemiological associations that
exist between RSV lower respiratory tract infections in early life
and the subsequent development of persistent wheezing and
asthma (10–13). Whether RSV infection in infancy causes subse-
quent alterations in airway function or whether underlying abnor-
malities predispose the young individual to develop persistent
lower airway dysfunction after RSV infection are issues that re-
main to be resolved (14, 15). Nevertheless, recurrent RSV infec-
tion is frequent at all ages (9, 16), and it is possible that the type
of host response that is elicited upon reinfection might distinguish
which children will develop persistent wheezing and possibly
asthma. We hypothesized that age at first RSV infection is a crit-
ical factor in determining the phenotype of airway response to
subsequent RSV infection. The present study was conducted in a
mouse model of RSV-induced AHR and inflammation. Mice were
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first infected with purified RSV shortly after birth (at 1 wk of
age) or at weaning (at 3 wk of age), then reinfected 5 wk later, after
complete resolution of AHR and airway inflammation. Airway
function, airway inflammation, and cytokine production were as-
sessed after both primary and secondary infections. The results
were compared with those obtained at the same time after primary
infection of age-matched animals and demonstrated the important
influence of age at first infection on the response to reinfection.
Materials and Methods
Animals
BALB/c mice were obtained from The Jackson Laboratory. Mice were
bred and maintained under pathogen-free conditions at the Biological Re-
source Center, National Jewish Medical and Research Center. Mice were
used under an experimental protocol approved by the institutional animal
care and use committee.
Virus preparation
Strain A2 of human RSV (catalogue no. VR-1302) was obtained from
American Type Culture Collection. Stocks of purified RSV were prepared
under endotoxin-free conditions and were assessed to be free of endotoxin
contamination using a Limulus amebocyte lysate-based Pyrogent Plus Gel
Clot assay with a sensitivity of 0.06 endotoxin units/ml (BioWhittaker;
catalogue no. N283-06). The virus was propagated in monolayers of HEp-2
cells (American Type Culture Collection; catalogue no. CCL-23) grown in
MEM (Invitrogen Life Technologies) supplemented with 5% FBS. At max-
imum cytopathic effect, the cells were harvested and disrupted by sonica-
tion in the same culture medium. The suspension was clarified by centrif-
ugation at 10,000 g for 15 min at 10°C, and the resulting supernatant was
layered on top of a sucrose gradient (30% in 50 mM Tris-buffered normal
saline solution containing 1 mM EDTA, pH 7.5) and additionally centri-
fuged at 100,000  g for 2 h at 10°C. The pellet containing purified virus
was resuspended in 10 mM PBS (pH 7.4) containing 15% sucrose and
stored in aliquots at 70°C. Viral titers were determined by a standard
plaque assay combined with immunostaining for RSV using a biotinylated
goat anti-human RSV Ab (Accurate Chemical & Scientific) and an avidin-
biotin peroxidase detection system (DakoCytomation). Uninfected HEp-2
cell cultures were similarly processed to obtain a control, virus-free, sham
preparation.
Experimental design
At the indicated ages, mice were inoculated intranasally with 106 PFU of
purified RSV, resuspended in 10 l (for 1-wk-old mice) or 20 l (for
mice aged 3 wk of age) of endotoxin-free PBS. Age-matched control
mice were inoculated with the virus-free, sham preparation or UV light
(UV)-inactivated RSV. Full inactivation of RSV, as assessed by viral
plaque assay, was achieved by exposing the viral suspension in a sterile
glass vial to an UV light source (302 nm Chromato-Vue Lamp UVM-57)
for 16 h at 4°C. The inactivated viral suspension was administered so that
each mouse received a number of virions that would be equivalent to 106
PFU of active virus. Except for the youngest age (1 wk old), all mice
were inoculated under light anesthesia (2.5% avertin, 0.01 ml/g body
weight). Airway function and airway inflammation were assessed at the
peak of the response, as shown previously (17), on day 6 after infection.
Immediately after measurement of airway function, the whole lung was
lavaged with 1 ml of HBSS (twice with 0.5 ml after primary infection for
the youngest animals), followed by fixation and processing of the right
lobes into paraffin (whole lung for youngest animals, after primary infec-
tion). The left lobe (or whole lung from separate experiments with the
youngest animals) was homogenized and used for determination of lung
viral titers and IL-13 levels. The murine IL-13R2-human IgG fusion pro-
tein (IL-13i; provided by Dr. D. D. Donaldson, Wyeth Pharmaceuticals,
Cambridge, MA), a potent IL-13 inhibitor of allergen-induced AHR and
inflammation (18), was prepared as previously described (19). IL-13i was
administered as previously reported (20) by i.p. injection (300 g/mouse)
24 h before and on days 1, 3, and 5 after infection.
Assessment of airway function
Airway function was assessed in anesthetized, mechanically ventilated an-
imals by measuring changes in lung resistance in response to increasing
doses of inhaled methacholine (MCh) as previously described (21). Data
are expressed as the percent change from baseline lung resistance obtained
after inhalation of saline.
Measurement of cytokines
Levels of IFN-, IL-4, and IL-5 were measured in bronchoalveolar lavage
fluid (BALF) using commercial ELISA kits according to the manufactur-
er’s instruction (BD Pharmingen). The detection limits of the assays were
as follows: IFN-, 62.5 pg/ml; IL-4, 7.8 pg/ml; and IL-5, 15.6 pg/ml. IL-13
was measured in lung tissue homogenate using a sensitive ELISA (limit of
detection, 1.5 pg/ml; R&D Systems), as previously described (20).
Assessment of airway inflammation and mucus production
Airway inflammation was assessed by total and differential counting of
cells recovered in BALF and by histopathological examination of lung
tissue sections stained with H&E. Tissue-infiltrating eosinophils were de-
tected by immunostaining of tissue sections using a polyclonal rabbit anti-
eosinophil major basic protein (MBP; provided by Dr. J. J. Lee, Mayo
Clinic, Scottsdale, AZ). Mucus-producing goblet cells were detected by
staining of tissue sections using the periodic acid-Schiff (PAS) method. For
quantitative analyses, the data were normalized to the perimeter of the
basement membrane (BM) of the airway epithelium as previously de-
scribed (22). The data are expressed as the mean  SEM of MBP and
PAS cells per millimeter of BM.
Detection of IL-13 in lung T cells
Intracellular IL-13 was detected by immunofluorescent staining of lung
CD4 and CD8 T cells, as previously described (23). Briefly, lung T cells
were isolated by collagenase digestion of lung tissue, followed by separa-
tion of mononuclear cells by density gradient centrifugation (Organon
Teknika). Lung mononuclear cells were stimulated in culture for 4 h with
PMA (5 ng/ml) and ionomycin (500 ng/ml) in the presence of brefeldin A
(10 g/ml). After staining for cell surface markers with CyChrome-con-
jugated anti-CD3 (Caltag Laboratories) and FITC-conjugated anti-CD4 or
anti-CD8 Abs (BD Pharmingen), cells were washed, fixed in paraformal-
dehyde (4% in PBS), and permeabilized with saponin (0.1% in PBS). After
incubation with normal goat serum to block nonspecific background stain-
ing, the permeabilized cells were incubated for 30 min with a biotinylated
goat anti-mouse IL-13 Ab or a similarly conjugated isotype-matching con-
trol Ab (R&D Systems). Cells were washed and stained for 30 min with
PE-conjugated streptavidin (BD Pharmingen). Staining was analyzed by
flow cytometry with gating on the CD3-positive cell population using
CellQuest software on a FACSCalibur (BD Biosciences).
Statistical analysis
Data are expressed as the mean  SEM of six to eight mice in each group.
Statistical significance at a level of p  0.05 was determined by ANOVA
using the StatView 4.5 statistical analysis software package (Abacus Con-
cepts). Differences between the groups were determined by multiple com-
parisons using Fisher’s protected least significant difference test.
Results
Age-related differences in airway responsiveness to primary RSV
infection
To examine whether the age at first infection determines the extent
of airway responsiveness to a primary RSV infection, mice were
first infected shortly after birth (1 wk of age) or at weaning (3 wk
of age). Airway function and airway inflammation were assessed
on day 6 after infection. Without infection, baseline resistance was
significantly higher in the youngest mice (mean  SEM, 2.25 
0.08 cm H2O/ml  s1), reflecting smaller airway size, compared
with weanling mice (mean SEM, 1.24 0.05 cm H2O/ml  s1;
p  0.01). Similar to sham-inoculated mice, mice inoculated with
UV-inactivated virus (uvRSV) exhibited normal airway respon-
siveness to inhaled MCh in both age groups (Fig. 1, A and B). After
RSV infection, the baseline resistance was not altered in any of the
age groups (2.36  0.08 cm H2O/ml  s1 for the youngest mice
and 1.36  0.06 cm H2O/ml  s1 for weanling mice). However,
RSV infection resulted in the development of AHR in response to
inhaled MCh in both age groups.
After primary infection, the numbers of lymphocytes recovered
in BALF were significantly increased for both age groups com-
pared with either sham-inoculated or uvRSV-inoculated, age-
matched control groups (Fig. 1, C and D). The extent of the lym-
phocytic response, however, was lower in the youngest group. In
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tissue, RSV infection resulted in the development of a character-
istic peribronchial and perivascular airway tissue infiltration pre-
dominantly by mononuclear cells (Fig. 2). Compared with mice
infected at weaning, mice infected at 1 wk of age showed more
mucus-producing cells in the airways (Fig. 2) and mild, but sig-
nificant, airway tissue eosinophilia (Table I).
Cytokine levels were measured and compared between the two
age groups. IFN- levels were higher in the BALF of RSV-in-
fected weanling mice, but were barely detected in the BALF of
RSV-infected newborn mice (Fig. 3A). By contrast, IL-13 levels
were significantly higher in lung tissue homogenates of RSV-in-
fected newborn mice compared with RSV-infected weanling mice
(Fig. 3B). The levels of IL-4 and IL-5 were at the limit of the assay
detection and were not different between the two age groups.
Virus replication and clearance were examined in the lungs of
both age groups by measuring the amounts of replicating virus
recovered from the lungs at different time points after inoculation.
No replicating virus was recovered from the lungs of uvRSV-in-
oculated mice (data not shown), and no significant differences
were detected between the two age groups in lung viral titers mea-
sured on day 1, 3, or 6 after RSV infection, indicating similar rates
of viral replication and clearance for both age groups (Fig. 3C).
RSV infection at weaning protects mice against the development
of AHR on reinfection
To define the pattern of airway response to a secondary RSV in-
fection in mice initially infected at weaning and after full recovery,
when no significant AHR or airway inflammation could be de-
tected after the primary infection (data not shown), these mice were
reinfected 5 wk later (at 8 wk of age). Airway function and airway
inflammation were assessed in these animals on day 6 after the sec-
ondary infection, and the results were compared with those obtained
in age-matched animals after primary infection with RSV (at 8 wk of
age) with or without prior inoculation of uvRSV at weaning.
Compared with mice infected only once, at 8 wk of age (Fig.
4A) or at 3 wk of age (Fig. 2), mice that were initially infected at
weaning and reinfected 5 wk later developed increased mononu-
clear airway tissue inflammation after secondary RSV infection
(Fig. 4C). Mucus production and tissue-infiltrating eosinophil
numbers, however, were not altered after secondary infection in
these animals (Table I). In parallel, the numbers of lymphocytes
recovered in BALF after reinfection at 8 wk were also increased
compared with the numbers of lymphocytes recovered after a pri-
mary infection at either 3 or 8 wk of age (Fig. 4D). By contrast,
inoculation of uvRSV at weaning did not alter the inflammatory re-
sponse to subsequent infection with live RSV at 8 wk of age (Fig. 4,
B and D). Most surprisingly, in contrast to age-matched control ani-
mals that developed significant AHR after a primary RSV infection at
8 wk of age, AHR was completely abolished in the reinfected animals
despite the intense inflammatory response that developed in the
lungs (Fig. 4E). In parallel, the peak viral titers were significantly
reduced in the lungs of these animals (Fig. 4F).
After secondary RSV infection, the levels of IFN- detected in
BALF were higher than those measured after a primary infection,
but the peak response was shifted to an earlier time point after
reinfection (Fig. 4G). By contrast, the amounts of IL-13 measured
in lung tissue homogenates were significantly reduced after rein-
fection of mice that were initially infected at weaning (Fig. 4H).
Neonatal RSV infection predisposes mice to the development of
eosinophilic airway inflammation and enhanced AHR after
reinfection
To determine whether early age at infection predisposes to more
severe alterations in airway responsiveness on RSV reinfection,
mice were infected shortly after birth (1 wk of age) and rein-
fected 5 wk later, when no significant AHR or airway inflamma-
tion could be detected after complete recovery from the primary
infection (data not shown). Airway function and airway inflam-
mation were assessed in these animals on day 6 after the secondary
infection, and the results were compared with those obtained in
age-matched animals that received a primary RSV infection (at 6
wk of age) with or without inoculation of uvRSV during the neo-
natal period (1 wk of age).
Compared with mice infected only once, either at 6 wk of age
(Fig. 5, A and D) or at 1 wk of age (Fig. 2), mice initially
infected at 1 wk of age and reinfected 5 wk later developed an
FIGURE 1. Primary RSV infection in newborn and weanling mice: air-
way function and BAL cellularity. Groups of mice were inoculated as
newborns (1 wk of age (1wk)) or at weaning (3 wk of age (3wk)) with
RSV (n  8/group), uvRSV (n  4/group), or a sham preparation (n 
6/group). Airway responsiveness to inhaled MCh (A and B) and bronchoal-
veolar lavage cellularity (C and D) were assessed on day 6 after infection.
In both age groups, primary RSV infection induced significant AHR and
lymphocyte accumulation in the airways. , Significant difference com-
pared with sham or uvRSV group (p  0.05).
FIGURE 2. Primary RSV infection in newborn and weanling mice: lung
histopathology. Lung tissue sections from RSV-infected or sham-inocu-
lated mice (same groups as in Fig. 1) were stained with H&E (left panels)
and PAS (right panels). In both age groups, RSV infection induced peri-
bronchial airway tissue inflammation (arrowheads) and marked mucus pro-
duction (arrows), which was higher in the youngest age group. Scale
bars  50 m.
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additional increase in airway tissue inflammation (Fig. 5C) asso-
ciated with markedly enhanced mucus production and pronounced
airway tissue eosinophilia (Fig. 5F and Table I) after the secondary
RSV infection. The numbers of lymphocytes recovered in the
BALF of these animals were significantly increased after second-
ary RSV infection compared with those recovered after a primary
infection in the age-matched group (Fig. 5G). Such altered re-
sponses, however, were not observed in animals that were first
inoculated as neonates with uvRSV and subsequently infected with
RSV 5 wk later (Fig. 5, B, E, and G). Unlike the primary infection,
where only rare eosinophils were recovered in the BALF, the sec-
ondary infection induced significant airway eosinophilia, as shown
by a markedly increased proportion and numbers of eosinophils in
the BALF. Interestingly, in contrast to the absence of AHR after
secondary infection in mice initially infected at weaning, AHR was
not only observed, but was further increased after reinfection in
mice that were initially infected early in postnatal life (Fig. 5H).
However, despite the enhanced AHR and lung histopathology, the
amounts of replicating virus recovered from the lungs of these
mice were not different from those in age-matched control animals,
which received a single RSV infection with or without previous
inoculation with uvRSV (Fig. 5I).
Although IFN- was barely detected in BALF of mice that were
infected only once, at 1 wk of age, the amounts of IFN- mea-
sured in BALF after reinfection at 6 wk of age were comparable to
those measured after either a primary or a secondary infection in
weanling mice (Fig. 5J). In parallel, the amounts of IL-13 detected
in lung tissue homogenates were further increased after reinfection
of mice that were initially infected at 1 wk of age (Fig. 5K).
Analysis of airway tissue-infiltrating T cells for intracellular
IL-13 content by immunostaining and flow cytometry revealed that
both CD4-positive and CD8-positive T cells expressed IL-13 (Fig.
6A), and the frequencies of these cells increased after reinfection of
these animals (Fig. 6B). Of note, treatment of these mice during the
secondary RSV infection with a recombinant murine IL-13R2-
human IgG fusion protein (IL-13i) completely abolished AHR
(Fig. 7A), indicating a central role for IL-13 in the altered airway
response to secondary RSV infection in mice initially infected
early in life. Inhibition of IL-13 also attenuated airway eosino-
philia, without altering mononuclear cell infiltration, in both BALF
(Fig. 7B) and airway tissue. The number (mean SEM) of airway
tissue-infiltrating, MBP-positive cells was significantly lower in
mice treated with IL13i (5.8  1.4/mm BM) than in mice treated
with control Ig (cIg; 18.3  3.4/mm BM; p  0.05). Furthermore,
IL-13 inhibition completely abolished mucus hyperproduction in
the airways of these animals (Fig. 7D). The number of PAS-pos-
itive goblet cells was dramatically reduced from 117  13.2
cells/mm BM in cIg-treated animals to 16.4 4.1 cells/mm BM in
IL-13i-treated animals ( p  0.05).
Discussion
The objective of this study was to define the role of age in the
development of altered airway function after reinfection with RSV.
FIGURE 3. Primary RSV infection in newborn and weanling mice: cy-
tokine levels and lung viral titers. BALF and lung tissue from RSV-in-
fected, uvRSV-inoculated, and sham-inoculated mice (same groups as in
Fig. 1) were examined for cytokine levels (A and B) and viral titers (C).
Compared with weanling mice, newborn mice showed markedly lower
levels of IFN- in BALF (A), but higher levels of IL-13 in lung tissue
homogenate (B), after RSV infection. Lung viral titers were similar in both
age groups (C). , Significant difference compared with sham or uvRSV
group (p  0.05); §, significant difference compared with RSV-infected
newborn mice (p  0.05); #, significant difference compared with day 2
postinfection values (p  0.05).
Table I. Age-related differences in airway tissue eosinophilia and goblet cell hyperplasia after primary (1°) and secondary (2°)
RSV infectiona
1° Infection Sham uvRSV RSV uvRSV RSV
2° Infection RSV RSV
Tissue eosinophils (MBP-positive cells/mm BM)
Age at 1° infection
1 wk 3.5  0.8 3.3  0.9 6.8  1.0b 2.2  0.8 15.6  3.8c
3 wk 0.7  0.3 0.5  0.3 2.1  0.9 1.5  0.6 0.5  0.1
6 wk 0.6  0.3 1.6  0.4
8 wk 0.6  0.2 1.3  0.4
Goblet cells (PAS-stained cells/mm BM)
Age at 1° infection
1 wk 4.5  1.2 5.0  0.9 21.6  3.0b 9.8  3.3b 125.3  15.8c
3 wk 1.3  0.2 1.8  0.5 13.3  2.5b 12.3  1.7b 10.0  2.3c
6 wk 1.1  0.2 11.0  2.4b
8 wk 1.0  0.3 10.4  2.3b
a Data are expressed as the mean number of cells (SEM) detected in central airways. Data are normalized to the length of airway epithelium BM.
b Significant difference compared with age-matched, sham-inoculated, control group ( p  0.05).
c Significant difference compared with 1° RSV in mice infected at 1 wk of age ( p  0.05).
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Because recurrent RSV infection is frequent at all ages in humans,
but the peak incidence for primary and secondary RSV-related
lower respiratory tract disease is in infancy (9, 16), we hypothe-
sized that the development of altered airway function during rein-
fection with RSV is determined in an age-dependent manner, at the
time of initial infection. As demonstrated in the present study,
neonatal RSV infection predisposes mice to develop more severe
airway disease on reinfection. This amplified and altered response
to reinfection is characterized by the development of significant
AHR associated with marked airway eosinophilia. By contrast,
primary infection at weaning elicited a protective airway response
to reinfection characterized by an increased inflammatory re-
sponse, predominantly lymphocytic, but without development of
AHR and airway eosinophilia. However, these divergent responses
to reinfection were not elicited if the mice were initially inoculated
with uvRSV, clearly demonstrating the requirement for active lung
viral infection during initial exposures. Most remarkably, viral
clearance was achieved at similar rates, and AHR developed to the
same extent in both age groups, after the primary infection. The
most distinctive differences between the two ages in terms of re-
sponse to primary RSV infection were lower IFN-, but increased
IL-13, levels in the lungs of neonatally infected animals. However,
after reinfection, greater amounts of IFN- were detected in BALF
and were comparable in both age groups. By contrast, after rein-
fection, the levels of IL-13 were further increased in mice initially
infected as neonates, but were virtually undetectable in mice ini-
tially infected at weaning. From these data it is clear that the con-
sequences of reinfection are established very early in life. Thus, if
infected early in life, the host might not be able to mount the
appropriate response that would protect against the consequences
of reinfection.
In general, recurrent RSV infection results in milder symptoms,
usually restricted to the upper respiratory tract in young children
and adults (24, 25), but in some cases more severe symptoms in-
volving the lower respiratory tract can develop after secondary
RSV infection, resulting in recurrent wheezing in younger chil-
dren. A recent prospective study evaluated RSV-specific T cell
responses in the peripheral blood of 55 infants hospitalized for
RSV bronchiolitis and found that the lymphoproliferative
responses to RSV stimulation in vitro were similar during both
acute and convalescent phases of bronchiolitis and were not en-
hanced after a subsequent episode of natural RSV infection during
FIGURE 4. Airway responsiveness to secondary RSV infection: effect of primary infection at weaning. Groups of mice were initially infected with RSV
(RSV(3wk)/RSV(8wk); n  8), inoculated with uvRSV (uvRSV(3wk)/RSV(8wk); n  4) at 3 wk of age and reinfected 5 wk later, or infected with RSV
(RSV(8wk); n 6) or sham inoculated (Sham(8wk); n 6) at 8 wk of age. Lung histopathology (A–C), bronchoalveolar lavage cellularity (D), and airway
responsiveness to inhaled MCh (E) were assessed on day 6 after reinfection. Lung viral titers (F) and levels of IFN- (G) and IL-13 (H) were measured
on days 2, 4, and 6 after reinfection. Infection at weaning elicited a protective airway response during reinfection. This was characterized by a more vigorous
mononuclear cell inflammation (C, arrowhead, and D) with no eosinophilia and no increase in mucus (C, arrow) production, but a complete abolition of
AHR (E). After the secondary infection, viral titers decreased (F), and IFN- levels increased with an early peak response (G), whereas IL-13 levels
decreased (H). Scale bars  50 m. , Significant difference compared with sham group (p  0.05); §, significant difference compared with either
RSV(8wk) or uvRSV(3wk)/RSV(8wk) (p  0.05); #, significant difference compared with day 2 postinfection values (p  0.05); †, significant difference
compared with levels measured on day 6 in either RSV(8wk) or uvRSV(3wk)/RSV(8wk) (p  0.05).
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the second winter season (26). These observations led the inves-
tigators to conclude that RSV-specific T cell responses do not pro-
vide protection against reinfection and to speculate that RSV-spe-
cific T cells may fail to expand in vivo after reinfection. However,
it is possible that these cells could be compartmentalized to spe-
cific locations in the lung and respond more vigorously in situ
upon secondary RSV infection, as demonstrated in previous ex-
perimental animal studies (27, 28). A recent study conducted in
mice suggested that the extent of the BALF inflammatory response
to reinfection in adulthood is determined by the age at first infec-
tion (29). They showed that the pattern of inflammatory (lympho-
cytic) response to reinfection in adulthood differs depending on the
age at first infection with RSV, and that neonatal infection primes
the host to develop a Th2-biased response. Our data not only ex-
tend these findings, but additionally demonstrate that the enhance-
ment of AHR during reinfection requires IL-13, is associated with
airway eosinophilia and mucus hyperproduction, and is determined
in an age-dependent manner at the time of initial infection with
RSV. This is contrasted with the protective response against de-
velopment of AHR and the absence of airway eosinophilia and
mucus production despite the marked BAL and lung lymphocytic
accumulation elicited on reinfection of mice initially infected at
weaning.
In both humans and animal models, the Th2 cytokine IL-13 has
been identified as a central mediator of AHR (18, 30). IL-13 is also
a major regulator of mucus production in the airways (31), and to
some degree it contributes to the development of airway eosino-
philia (32). The role of IL-13 in RSV-mediated airway disease is
to some extent controversial. IL-13 production is increased along
with that of other Th2 cytokines in the lungs of mice previously
primed with formalin-inactivated RSV and subsequently infected
with live virus (33). Unlike formalin-inactivated RSV, the secreted
form of the attachment G glycoprotein of RSV appears to prefer-
entially prime the animals to develop high levels of IL-5 and IL-13
and pulmonary eosinophilia, even in the complete absence of IL-4
(34). Given the marked increases in IL-13 production detected in
the present study, especially in mice reinfected after primary infection
as neonates, we determined the cellular source of this cytokine and
defined its role in the development of mucus production, airway eo-
sinophilia, and AHR in this group. Intracellular staining of isolated
FIGURE 5. Airway responsiveness
to secondary RSV infection: effect of
primary neonatal infection. Groups of
mice were initially infected with RSV
(RSV(1wk)/RSV(6wk); n  8), inocu-
lated with uvRSV (uvRSV(1wk)/
RSV(6wk); n 4) at1 wk of age and
reinfected 5 wk later; or infected with
RSV (RSV(6wk); n  6) or sham in-
oculated (Sham(6wk); n 6) at 6 wk of
age. Lung histopathology (A–F), bron-
choalveolar lavage cellularity (G), and
airway responsiveness to inhaled MCh
(H) were assessed on day 6 after rein-
fection. Lung viral titers (I) and levels
of IFN- (J) and IL-13 (K) were mea-
sured on days 2, 4, and 6 after reinfec-
tion. After neonatal infection, second-
ary RSV infection resulted in the
development of an enhanced lung his-
topathology (C), characterized by
marked increases in airway tissue in-
flammation (arrowhead), mucus hyper-
production (arrow), and the appearance
of eosinophilia in airway tissue (F, ar-
rows) and BALF (G). Reinfection of
this age group also resulted in enhanced
AHR (H). Despite these changes, the
rates of viral replication or clearance
were unaffected in this group (I). How-
ever, IFN- levels increased with an
early peak response (J), whereas IL-13
levels further increased on day 6 after
the secondary infection (K). Scale
bars 50 m. , Significant difference
compared with sham group (p  0.05);
§, significant difference compared with
either RSV(6wk) or uvRSV(1wk)/
RSV(6wk) (p  0.05); #, significant
difference compared with day 2 postin-
fection values (p  0.05); †, significant
difference compared with levels mea-
sured on day 6 in either RSV(6wk) or
uvRSV(1wk)/RSV(6wk) (p  0.05).
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lung T cells revealed that both CD4 and CD8 T cells were a source of
IL-13, and the frequency of these cells was significantly increased
after reinfection of the youngest mice. Furthermore, treatment of these
animals with murine IL-13R2-human IgG fusion protein during sec-
ondary RSV infection completely abolished the development of AHR
and mucus production and significantly inhibited airway eosinophilia.
In contrast to our earlier studies of the role of IL-13 in primary RSV
infection (20), these data clearly identified IL-13 as a central mediator
involved in the development of AHR after reinfection of mice initially
infected as neonates.
The role of IFN- in RSV-mediated airway disease is not clear.
Several clinical studies have described an imbalance in Th1/Th2
cytokine expression with a predominant Th2-like response. This
has been generally attributed to deficient IFN- production, asso-
ciated with lower respiratory tract disease in infants and young
children with documented RSV infection (35–38). More recently,
a prospective study examined type 1 and type 2 cytokine responses
in high risk infants (at least one atopic parent with asthma) to their
first natural RSV infection and related the response to the onset of
disease (39). In particular, the levels of IFN- measured in nasal
lavage samples taken at the first signs of symptoms were signifi-
cantly lower in infants who developed lower respiratory tract dis-
ease (bronchiolitis) than in those who developed upper respiratory
symptoms alone. When PBMC were stimulated in vitro, deficient
IFN- production could also be demonstrated in infants with more
severe symptoms, corroborating the results obtained in vivo.
IFN- production is restricted to T cells and NK cells. Although
produced in large amounts in the lungs of RSV-infected adult
mice, IFN- did not appear to be involved in the development of
AHR (40). The present study provides additional evidence that
IFN- is not involved in the development of AHR. In particular,
AHR was completely abolished after reinfection despite high lev-
els of IFN- in the lungs of mice that were initially infected at
weaning. Similarly, IFN- was not apparently protective, because
mice infected at1 wk of age and reinfected 5 wk later developed
enhanced AHR despite high levels of IFN-. As demonstrated by
the inhibition studies, IL-13 appears to be a major regulator of
AHR and mucus hyperproduction after reinfection. It is well known that immune responses change with advancing
age. In general, the responses are compared at widely different
ages; in the mouse aged is defined as older than 6 mo in some
studies. In contrast, it appears that significant differences in terms
of the consequences of re-exposure are established very early in
life. Thus, in an allergen challenge model, the age at initial sen-
sitization was critical in dictating the degree of airway (eosino-
philic) inflammation, the profile of cytokine production, and AHR
on subsequent allergen challenge (41). In an analogous fashion, the
present study demonstrates that the age at first RSV infection, even
within the narrow window of primary infection at 1 wk vs primary
infection at 3 wk, is sufficient to establish the consequences of
reinfection. It is not entirely clear what the underlying mechanisms
are. It is possible, at least in part, that a neonatal deficiency in
IFN- production during primary infection, perhaps due to imma-
turity of the host immune response rather than the result of an
aberrant response to viral infection, allows for the development of
an unopposed, Th2-biased response that persists and can be re-
stimulated during subsequent infection by RSV. However, it is
unlikely that simple differences in the levels of IFN- dictate or
account for this narrow window of susceptibility. IL-13 does
emerge as a major regulator, at least of the enhanced response to
reinfection of young mice. When extrapolated to the human situ-
ation and exposures in the neonate/young infant, these studies
highlight the importance of developing preventative or delaying
strategies, so that the consequences of initial RSV infection may be
mitigated by the age at which they occur.
FIGURE 6. Cellular source of IL-13 production in the lung after the
secondary infection in mice initially infected as neonates (same groups as
described in Fig. 5). T cells were isolated from collagenase-digested lung
tissue and simultaneously stained for surface expression of CD3 and CD4
or CD8, followed by intracellular staining for IL-13 and analysis of ex-
pression by flow cytometry. A, Representative flow cytometry panels
showing IL-13-expressing lung T cells in the three groups of mice. B,
Proportion (mean  SEM) of IL-13-expressing lung T cells. Both CD4-
positive and CD8-positive lung T cells expressed IL-13, and the propor-
tions of these cells were further increased after the secondary infection
compared with primary infection. , Significant difference compared with
sham group (p  0.05); §, significant difference compared with RSV(6wk)
(p  0.05).
FIGURE 7. Role of IL-13 in the development of enhanced AHR, airway
inflammation, and mucus production during secondary RSV infection.
Mice were initially infected as neonates and treated with IL-13i
(RSV(1wk)/RSV(6wk)  IL-13i; n  6) or control Ig (RSV(1wk)/
RSV(6wk)  cIg; n  6) during reinfection. Airway responsiveness to
inhaled MCh (A), bronchoalveolar lavage cellularity (B), and lung histo-
pathology (C and D) were assessed on day 6 after the secondary infection.
Neutralization of IL-13 resulted in significant inhibition of AHR (A) and
airway eosinophilia in both bronchoalveolar lavage (B) and tissue (see
text), and abolished mucus hyperproduction in the airways (D, arrows)
without altering mononuclear airway inflammation in bronchoalveolar la-
vage (B) or tissue (C and D, arrowheads). Scale bars  50 m. , Signif-
icant difference compared with sham group (p  0.05); §, significant dif-
ference compared with cIg-treated group (p  0.05).
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